Results 31 to 40 of about 11,103 (274)

Glucocorticoids and Mepolizumab in Eosinophilic Asthma

open access: yesNew England Journal of Medicine, 2014
report that treatment with mepolizumab, a monoclonal antibody against interleukin-5, allowed a modest reduction in the maintenance dose of oral gluco -corticoids in patients who had severe eosino-philic asthma. The absolute reduction in the median dose of prednisone in the mepolizumab group was from 10.0 mg per day to 3.1 mg per day (as compared with a
Bel, E, Ortega, H, Pavord, I
openaire   +7 more sources

The Role of ACT Score in Mepolizumab Discontinuation

open access: yesJournal of Asthma, 2023
AbstractBackgroundMepolizumab is a therapy for severe asthma. However, studies on mepolizumab with external validity and diverse population from the US are lacking. There is little knowledge of the characteristics of people that discontinue mepolizumab in clinical care.ObjectiveTo investigate the real-world efficacy and time to clinical discontinuation
Neha Solanki   +14 more
openaire   +2 more sources

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

open access: yesAllergy, Asthma & Clinical Immunology, 2021
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian   +3 more
doaj   +1 more source

Characteristics of new adult users of mepolizumab with asthma in the USA

open access: yesBMJ Open Respiratory Research, 2021
Background In the USA, over 25 million people have asthma; 5%–10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for ...
Pamela M McMahon   +11 more
doaj   +1 more source

Diagnosis and management of eosinophilic asthma: a US perspective. [PDF]

open access: yes, 2014
Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and ...
Doherty, Taylor A, Walford, Hannah H
core   +1 more source

Churg-Strauss Syndrome with Necrosis of Toe Tips [PDF]

open access: yes, 2011
Churg-Strauss syndrome (CSS) is a granulomatous necrotizing vasculitis of unknown etiology associated with bronchial asthma. Despite affecting small to medium-sized vessels, necrosis of the digits due to vasculitis is extremely rare.
Hasegawa, Kenjiro   +9 more
core   +1 more source

Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein–protein interaction analyses

open access: yesRespiratory Research, 2023
Introduction Biomarkers are needed to inform the choice of biologic therapy in patients with asthma given the increasing number of biologics. We aimed to identify proteins associated with response to omalizumab and mepolizumab.
Ayobami Akenroye   +4 more
doaj   +1 more source

Eosinophil Apoptosis and Clearance in Asthma [PDF]

open access: yes, 2013
Peer reviewedPublisher ...
Bickham U.R.   +9 more
core   +3 more sources

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

open access: yesFrontiers in Pharmacology, 2023
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps.
Fan Zou   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy